MLTX Insider Phillips Andrew John Buys 22,195 Shares
Phillips Andrew John bought 22,195 shares of MoonLake Immunotherapeutics on June 17, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Phillips Andrew John bought 22,195 shares of MoonLake Immunotherapeutics ($MLTX) on June 17, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $MLTX is up 4.2% after 1 week, up 2.5% after 1 month and down 50.2% to date (from the $19.19 close on Jun 17, 2026).
MLTX
MoonLake Immunotherapeutics
Key Points
- On June 17, 2026, Andrew John Phillips bought 22,195 shares of MoonLake Immunotherapeutics, valued around $496,000 at the current price of $22.38 per share.
- The stock has seen a significant rise from its 52-week low of $5.95, closing at $12.39 before Phillips' purchase.
- Analysts give the stock a consensus rating of 'buy' with a mean price target of $28.54 based on 13 opinions.
Get $MLTX trade alerts by text
We text you when insiders, Congress or big funds trade $MLTX. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated MoonLake Immunotherapeutics alert may contain errors. Disclosures
Insider Buying and Selling at MoonLake Immunotherapeutics
On June 17, 2026, Andrew John Phillips bought 22,195 shares of MoonLake Immunotherapeutics (MLTX) on the NasdaqCM. At the current share price of $22.38, this transaction is valued at approximately $496,000. This purchase comes as the company continues to develop its therapies for inflammatory diseases.
Other Insiders Active on the Same Day
On the same day, several other insiders also made notable transactions. Ramnik Xavier, Spike Loy, and Catherine Moukheibir each bought 22,195 shares, though their purchase prices were not disclosed. Additionally, Matthias Bodenstedt, the Chief Financial Officer, sold 15,082 shares in a planned transaction, valued at about $296,814 based on a price of $19.68 per share.
Stock Performance and Analyst Ratings
MoonLake Immunotherapeutics has experienced a strong uptick in its stock price, moving up from its 52-week low of $5.95 to a closing price of $12.39 prior to Phillips' purchase. The stock is well above its 50-day moving average of $16.51. Analysts remain optimistic, with HC Wainwright & Co. recently maintaining a 'buy' rating and a price target of $50.00 on October 5, 2026.
What MoonLake Immunotherapeutics Does
MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing treatments for inflammatory skin and joint diseases. The company's lead product, Sonelokimab, targets various inflammatory conditions, making its insider trades particularly relevant as it continues to advance in clinical trials.
What's Ahead for MoonLake Immunotherapeutics
Investors should keep an eye on the next earnings report, scheduled for November 5, 2026. The recent insider activity reflects confidence in the company's ongoing developments. Remember, this 13F filing reflects holdings as of the reporting period and may not represent the investors' current positions.
Related Filing Alerts
Source: Phillips Andrew John's Form 4 filing on $MLTX (Jun 17, 2026). Find the original filing: MLTX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts